MIRA Pharmaceuticals (MIRA) News Today → The Worst is Yet to Come… (From Porter & Company) (Ad) Free MIRA Stock Alerts $0.82 +0.02 (+2.51%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 1:18 AM | americanbankingnews.comReviewing MIRA Pharmaceuticals (MIRA) and Its RivalsMay 29, 2024 | prnewswire.comMira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled SubstanceMay 22, 2024 | finance.yahoo.comMIRA Announces Important Collaboration PotentialMay 22, 2024 | benzinga.comLatest News for Mira Pharmaceuticals Stock (NASDAQ:MIRA)May 21, 2024 | prnewswire.comMIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine AnalogMay 20, 2024 | prnewswire.comMira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine AnalogMay 14, 2024 | finance.yahoo.comMIRA Focuses on Potential Game-Changing Drug SubmissionApril 17, 2024 | msn.comMIRA Pharmaceuticals (MIRA) Price Target Decreased by 27.31% to 16.83April 2, 2024 | msn.comFDA clears first digital treatment for depression, but experts caution that research is still earlyApril 2, 2024 | marketwatch.comMIRA Pharmaceuticals Sees Positive Trial Results for Ketamir-2April 2, 2024 | markets.businessinsider.comMira Pharmaceuticals Steps Closer To Ketamir-2 IND Submission After Positive Preclinical ResultsApril 2, 2024 | finance.yahoo.comMIRA Making Strides Toward Breakthrough TreatmentApril 2, 2024 | prnewswire.comMira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND SubmissionMarch 28, 2024 | msn.com‘Ninja,’ Twitch’s biggest streamer, diagnosed with skin cancerMarch 28, 2024 | msn.comClarence Thomas and Samuel Alito dust off 150-year-old Comstock Act to target abortion rightsMarch 21, 2024 | prnewswire.comMIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific AdvisorMarch 18, 2024 | ca.finance.yahoo.comThere are ways to improve the London Stock Exchange crisis, but they’re not prettyMarch 12, 2024 | finance.yahoo.comBaker Hill Nominated for Tech Company of the Year in TechPoint's 25th Annual Mira AwardsMarch 8, 2024 | msn.comALS drug fails large clinical trial and may be withdrawn from marketMarch 8, 2024 | msn.comMedical Marijuana-Focused Mira Pharmaceuticals Stock Surges After Neuropsychiatric Disorders Update - Here's WhyMarch 8, 2024 | investorplace.comWhy Is Mira Pharmaceuticals (MIRA) Stock Up 52% Today?March 1, 2024 | msn.comEl Salvador -India strengthen ties: Adriana Mira unveils path to bilateral cooperationFebruary 23, 2024 | ca.finance.yahoo.comMaternal mental health conditions drive climbing death rate in US, research saysFebruary 6, 2024 | finance.yahoo.comIs MIRA Pharmaceuticals (NASDAQ:MIRA) In A Good Position To Deliver On Growth Plans?February 5, 2024 | finanznachrichten.deMIRA Pharmaceuticals, Inc.: MIRA Pharmaceuticals Provides Corporate UpdateFebruary 5, 2024 | markets.businessinsider.comMIRA Pharmaceuticals Partners Pharmaseed To Conduct Pre-Clinical Studies On KetamirFebruary 5, 2024 | finance.yahoo.comMIRA Pharmaceuticals Provides Corporate UpdateJanuary 30, 2024 | finance.yahoo.comWearable Sensors Market Size Worth USD 11.05 Billion in 2032 | Emergen ResearchJanuary 29, 2024 | msn.comADHD medication recalled due to pill mixupDecember 20, 2023 | investing.comMira Pharmaceuticals (MIRA) Earnings Dates & ReportsDecember 18, 2023 | msn.comMIRA Pharmaceuticals files to sell up to 1.7M shares for holdersDecember 16, 2023 | seekingalpha.comIPO Update: Telomir Pharmaceuticals Proposes IPO TermsDecember 4, 2023 | markets.businessinsider.comMIRA Pharma: AI Simulation On MIRA1a Shows Advantages Over Plant-Based Medical MarijuanaDecember 4, 2023 | finance.yahoo.comMIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence SimulationsDecember 1, 2023 | marketbeat.comTrading was temporarily halted for "MIRA" at 12:12 PM with a stated reason of "LULD pause."November 29, 2023 | finance.yahoo.comMIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%November 27, 2023 | finance.yahoo.comMIRA Makes Great Deal for Potential BlockbusterNovember 22, 2023 | seekingalpha.comAQB, BIVI and SHOT among mi-day moversNovember 22, 2023 | morningstar.comMira Pharmaceuticals IncNovember 21, 2023 | morningstar.comMira Pharmaceuticals Inc MIRANovember 21, 2023 | finance.yahoo.comMIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1aNovember 21, 2023 | finance.yahoo.comMIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern TimeNovember 20, 2023 | markets.businessinsider.comMIRA Pharma Partners With MIRALOGX For Licensing Agreement For Ketamir-2November 20, 2023 | marketwatch.comShares of MIRA Pharmaceutical Soar 92% on Licensing Agreement for Ketamine TreatmentNovember 20, 2023 | msn.comWhy Is Depression Focused MIRA Pharmaceuticals Stock Trading Higher Today?November 20, 2023 | marketbeat.comTrading was temporarily halted for "MIRA" at 10:11 AM with a stated reason of "LULD pause."November 20, 2023 | marketbeat.comTrading was temporarily halted for "MIRA" at 10:11 AM with a stated reason of "LULD pause." Trading set to resume at 10:11 AM. November 20, 2023 | marketbeat.comTrading was temporarily halted for "MIRA" at 10:11 AM with a stated reason of "LULD pause."November 20, 2023 | marketbeat.comTrading was temporarily halted for "MIRA" at 10:11 AM with a stated reason of "LULD pause."November 20, 2023 | nz.finance.yahoo.comOpenAI appoints former Twitch boss Emmett Shear CEO after shock departure of Sam Altman Get MIRA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now MIRA Media Mentions By Week MIRA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIRA News Sentiment▼0.580.76▲Average Medical News Sentiment MIRA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIRA Articles This Week▼41▲MIRA Articles Average Week Get MIRA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Kezar Life Sciences News Today Lexaria Bioscience News Today CASI Pharmaceuticals News Today Equillium News Today Kronos Bio News Today Daré Bioscience News Today Clene News Today NextCure News Today Ocuphire Pharma News Today Eagle Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIRA) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
